Initiate first sales of Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“2021 will also mark our first sales of a biologic therapeutic product – Pathogen Reduced Cryoprecipitated Fibrinogen Complex.”
What we found
Evidence strength A What the grades mean
The company did not report achieving first sales of the Pathogen Reduced Cryoprecipitated Fibrinogen Complex in 2021; subsequent filings continue to list the commercialization of this product as a future goal.
-
A Cerus Corp. 10-Q filed 2022-05-05
“our ability to successfully commercialize INTERCEPT Fibrinogen Complex, or IFC, and pathogen reduced cryoprecipitate-poor plasma;” ✓ confirmed on the page
-
A Cerus Corp. 8-K filed 2022-02-22
“Two of the Company’s blood center production partners, Gulf Coast Regional Blood Center and Central California Blood Center (CCBC), have recently obtained BLA approvals for the INTERCEPT Blood System for Cryoprecipitation” ✓ confirmed on the page
Market reaction: the shares moved +3.7% against the S&P 500 over the three sessions around the disclosure (4 May 2022 to 9 May 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- First sales of Pathogen Reduced Cryoprecipitated Fibrinogen Complex
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Cerus Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CERS-021644 · Corrections policy